Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study
Cepaityte, Dainora; Siafis, Spyridon; Egberts, Toine; Leucht, Stefan; Kouvelas, Dimitrios; Papazisis, Georgios
(2021) Schizophrenia bulletin, volume 47, issue 3, pp. 672 - 681
(Article)
Abstract
An association between antipsychotic drugs and pneumonia has been demonstrated in several studies; however, the risk for pneumonia caused by specific antipsychotics has not been extensively studied. The underlying mechanism is still unknown, and several receptor mechanisms have been proposed. Therefore, using a combined pharmacovigilance-pharmacodynamic approach, we aimed to investigate
... read more
safety signals of US Food and Drug Administration (FDA)-approved antipsychotics for reporting pneumonia and the potential receptor mechanisms involved. A disproportionality analysis was performed to detect a signal for reporting "infective-pneumonia"and "pneumonia-aspiration"and antipsychotics using reports submitted between 2004 and 2019 to the FDA adverse events spontaneous reporting system (FAERS) database. Disproportionality was estimated using the crude and the adjusted reporting odds ratio (aROR) and its 95% confidence interval (CI) in a multivariable logistic regression. Linear regressions investigated the relationship between aROR and receptor occupancy, which was estimated using in vitro receptor-binding profiles. Safety signals for reporting infective-pneumonia were identified for clozapine (LL = 95% 3.4, n = 546 [aROR: 4.8]) as well as olanzapine (LL = 95% 1.5, n = 250 [aROR: 2.1]) compared with haloperidol, while aRORs were associated with higher occupancies of muscarinic receptors (beta =. 125, P-value =. 016), yet other anti-muscarinic drugs were not included as potential confounders. No safety signals for reporting pneumonia-aspiration were detected for individual antipsychotics. Multiple antipsychotic use was associated with both reporting infective-pneumonia (LL 95%: 1.1, n = 369 [aROR:1.2]) and pneumonia-aspiration (LL 95%: 1.7, n = 194 [aROR: 2.0]). Considering the limitations of disproportionality analysis, further pharmacovigilance data and clinical causality assessment are needed to validate this safety signal.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: antipsychotics, disproportionality, FAERS, pneumonia, safety signal, Psychiatry and Mental health, Journal Article
ISSN: 0586-7614
Publisher: Oxford University Press
Note: Funding Information: None. SL has received honoraria as a consultant/advisor and/or for lectures from Angelini, Bohringer Ingelheim, Geodon & Richter, Janssen, Johnson &Johnson, Lundbeck, LTS Lohmann, MSD, Otsuka, Recordati, SanofAventis, Sandoz, Sunovion, TEVA. The rest of the authors declare no conflicts of interest. Publisher Copyright: © 2020 The Author(s). Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.All rights reserved. For permissions, please email: journals.permissions@oup.com. © The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.All rights reserved. For permissions, please email: journals.permissions@oup.com.
(Peer reviewed)